ArticleCancer immunology, immunotherapy : CII2025

Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.

Xin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.